Hantz Financial Services Inc. Sells 7,514 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Hantz Financial Services Inc. cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 3.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 219,171 shares of the company’s stock after selling 7,514 shares during the period. Hantz Financial Services Inc.’s holdings in Takeda Pharmaceutical were worth $2,902,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its position in shares of Takeda Pharmaceutical by 15.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 114,254 shares of the company’s stock valued at $1,478,000 after acquiring an additional 15,075 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Takeda Pharmaceutical by 153.7% in the 2nd quarter. AQR Capital Management LLC now owns 90,013 shares of the company’s stock worth $1,165,000 after buying an additional 54,539 shares during the last quarter. EP Wealth Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical during the 2nd quarter valued at about $194,000. Sanctuary Advisors LLC bought a new position in shares of Takeda Pharmaceutical in the 2nd quarter valued at about $454,000. Finally, GAMMA Investing LLC increased its stake in Takeda Pharmaceutical by 136.1% during the third quarter. GAMMA Investing LLC now owns 6,295 shares of the company’s stock worth $90,000 after acquiring an additional 3,629 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 2.7 %

Shares of TAK stock opened at $13.68 on Friday. The company has a market cap of $43.51 billion, a PE ratio of 23.58, a price-to-earnings-growth ratio of 0.24 and a beta of 0.51. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77. The stock’s 50 day simple moving average is $13.30 and its two-hundred day simple moving average is $13.89. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 6.49% and a return on equity of 10.00%. Research analysts predict that Takeda Pharmaceutical Company Limited will post 1.55 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.